<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553042</url>
  </required_header>
  <id_info>
    <org_study_id>CR108883</org_study_id>
    <secondary_id>42847922MDD1018</secondary_id>
    <nct_id>NCT04553042</nct_id>
  </id_info>
  <brief_title>A Study of Seltorexant in Healthy Participants</brief_title>
  <official_title>A Single-Dose, Open-Label, Randomized, Crossover Study to Assess the Bioequivalence Between Different Formulations and Phase 3 Formulation of Seltorexant Under Fasted Conditions in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bioequivalence of Test 1 and/or Test 2&#xD;
      seltorexant tablet formulations with respect to Reference seltorexant tablet formulation in&#xD;
      healthy participants receiving a single dose under fasted conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Seltorexant and its Metabolites</measure>
    <time_frame>Predose, up to 48 hours post dose (Day 3)</time_frame>
    <description>Cmax is defined as the maximum observed plasma concentration of seltorexant and its metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Last Observed Measurable Plasma Concentration (Clast) of Seltorexant and its Metabolites</measure>
    <time_frame>Predose, up to 48 hours post dose (Day 3)</time_frame>
    <description>Clast is defined as the last observed measurable (non-below quantification limit [non-BQL]) plasma concentration of seltorexant and its metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Seltorexant and its Metabolites</measure>
    <time_frame>Predose, up to 48 hours post dose (Day 3)</time_frame>
    <description>Tmax is defined as the actual sampling time to reach the maximum observed plasma concentration of seltorexant and its metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Time of the Last Measurable Plasma Concentration (AUC [0-last]) of Seltorexant and its Metabolites</measure>
    <time_frame>Predose, up to 48 hours post dose (Day 3)</time_frame>
    <description>AUC (0-last) is defined as area under the plasma concentration-time curve from the time of dosing to the last measurable plasma concentration of seltorexant and its metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity]) of Seltorexant and its Metabolites</measure>
    <time_frame>Predose, up to 48 hours post dose (Day 3)</time_frame>
    <description>AUC (0-infinity) is defined as area under the plasma concentration-time curve of seltorexant and its metabolites extrapolated to infinity, calculated using the linear trapezoidal method from time zero to infinite time calculated as the sum of AUC(0-last)+C(last)/ lambda(z).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Elimination Half-life (t1/2) of Seltorexant and its Metabolites</measure>
    <time_frame>Predose, up to 48 hours post dose (Day 3)</time_frame>
    <description>Apparent elimination half-life associated with the terminal slope lambda(z) of the semilogarithmic drug concentration-time curve of seltorexant and its metabolites.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) including AEs of Special Interest (AESI) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 11 Weeks</time_frame>
    <description>Number of participants with an AE including AE of special interest as a measure of safety and tolerability will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a investigational or non-investigational medicinal product. An AE does not necessarily have a causal relationship with the treatment. AESI will comprise of cataplexy, sleep paralysis, complex, sleep-related behaviors/parasomnias, sleep terrors, bruxism, sleep sex, sleep related eating disorder, sleep behavior disorder, catathrenia and abnormal (vivid) dreams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Laboratory Abnormalities</measure>
    <time_frame>Up to 11 Weeks</time_frame>
    <description>Number of participants with laboratory abnormalities related to hematology, serum chemistry, coagulation, and urinalysis will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes in Vital Signs</measure>
    <time_frame>Up to 11 Weeks</time_frame>
    <description>Number of participants with clinically significant changes in vital signs including blood pressure, heart rate, respiratory rate, oral temperature will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Abnormalities in Electrocardiogram (ECG)</measure>
    <time_frame>Up to 11 Weeks</time_frame>
    <description>Number of participants with abnormalities in ECG will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes in Physical Examination</measure>
    <time_frame>Up to 11 Weeks</time_frame>
    <description>Number of participants with clinically significant changes in physical examination including height and body weight will be reported.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of seltorexant as formulation (Test 1) (Treatment A) in Treatment Period 1, followed by a single dose of seltorexant as formulation (Test 2) (Treatment B) in Treatment Period 2, followed by a single dose of seltorexant as formulation (Reference) (Treatment C) in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment C in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence CBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence ACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment B in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence BAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3 on Day 1 of each Treatment Period under fasted condition. There will be a washout period of 7 to 14 days from dosing on Day 1 of each Treatment Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seltorexant</intervention_name>
    <description>Seltorexant will be administered orally as per assigned treatment sequence.</description>
    <arm_group_label>Treatment Sequence ABC</arm_group_label>
    <arm_group_label>Treatment Sequence ACB</arm_group_label>
    <arm_group_label>Treatment Sequence BAC</arm_group_label>
    <arm_group_label>Treatment Sequence BCA</arm_group_label>
    <arm_group_label>Treatment Sequence CAB</arm_group_label>
    <arm_group_label>Treatment Sequence CBA</arm_group_label>
    <other_name>JNJ-42847922</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be healthy on the basis of medical history (screening only), physical examination,&#xD;
             vital signs, and 12-lead electrocardiogram (ECG) performed at screening and Day-1 of&#xD;
             Treatment Period 1 or prior to randomization&#xD;
&#xD;
          -  Be healthy on the basis of clinical laboratory tests performed at screening&#xD;
&#xD;
          -  All female participants (regardless of childbearing potential), must have a negative&#xD;
             serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and a&#xD;
             negative urine pregnancy test on Day-1 of each treatment period&#xD;
&#xD;
          -  Body mass index (BMI) between 18.0 and 30.0 kilogram per meter square (kg/m^2,&#xD;
             inclusive (BMI = weight/height^2), and body weight not less than 50 kilogram (kg)&#xD;
&#xD;
          -  Blood pressure (after the participant is supine for 5 minutes) between 90 and 140&#xD;
             millimeter of Mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of or current clinically significant medical illness including (but not&#xD;
             limited to) cardiac arrhythmias or other cardiac disease, hematologic disease,&#xD;
             coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid&#xD;
             abnormalities, significant pulmonary disease, including bronchospastic respiratory&#xD;
             disease, diabetes mellitus, hepatic or renal insufficiency (estimated glomerular&#xD;
             filtration rate [eGFR] less than (&lt;) 80 milliliter per minute (mL/min)/1.73 per meter&#xD;
             square (m^2) at screening only), thyroid disease, neurologic (including seizure&#xD;
             disorders) or psychiatric disease (depression or anxiety disorder in remission and no&#xD;
             longer requiring medication is acceptable), infection, or any other illness that the&#xD;
             investigator considers should exclude the participant or that could interfere with the&#xD;
             interpretation of the study results. Significant past gastrointestinal medical&#xD;
             history, or any disease/surgery that would with interfere drug absorption&#xD;
&#xD;
          -  Has any significant or is suspected to have a primary sleep disorder, including but&#xD;
             not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias based on&#xD;
             history and/or physical exam. Participants with insomnia disorder are allowed if not&#xD;
             requiring medication&#xD;
&#xD;
          -  Use of any prescription or nonprescription medication (including vitamins and herbal&#xD;
             supplements), except for acetaminophen, oral contraceptives, and hormonal replacement&#xD;
             therapy within 14 days before the first dose of the study drug is scheduled&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to seltorexant or its excipients&#xD;
&#xD;
          -  Positive test for human immunodeficiency virus (HIV)-1 and HIV-2 antibodies, hepatitis&#xD;
             B surface antigen (HbsAg), or hepatitis C antibodies at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108883</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

